Clicky

COSMO Pharmaceuticals SA(COPN)

Description: Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.


Keywords: Medicine Pharmaceutical Clinical Medicine Artificial Intelligence Pharmaceutical Products Solid Tumors Colorectal Cancer Endoscopy Irritable Bowel Syndrome Gynaecology Polyp Diagnostic Gastroenterology Acne Vulgaris Androgenetic Alopecia Enema Large Intestine Colonoscopy Remimazolam Colorectal Polyp Adenomas Bile Acid Diarrhea Early Stage Cancers Lialda Lialda/Mezavant Methylene Blue Mmx Minimal Hepatic Encephalopathy Moderate Ulcerative Colitis Rifamycin Traveler's Diarrhea Uceris

Home Page: www.cosmopharma.com

Riverside II
Dublin, 2
Ireland
Phone: 353 1 817 0370


Officers

Name Title
Mr. Mauro Severino Ajani Founder & Exec. Chairman
Mr. Alessandro E. Della Cha LL.M CEO & Exec. Director
Mr. Ngo Dinh Nhan Head of R&D - AI & Biomedical IT
Mr. Giulio Evangelisti Head of Production, AI & Biomedical IT
Mr. Niall Donnelly Chief Financial Officer
Mr. Marco Lecchi Chief Operating Officer
Mr. Davide Malavasi Qualified Person & Technical Director
Mr. Luigi Longo Chief Scientific Officer
Ms. Hazel Winchester Head of Investor Relations
Mr. Biagio Vigano Chief People Officer

Exchange: SW

Country: CH : Switzerland

Currency: Swiss Franc (CHF)

Forward PE: 25.5754
Trailing PE: 28.5446
Price-to-Book MRQ: 2.2088
Price-to-Sales TTM: 12.9535
IPO Date:
Fiscal Year End: December
Full Time Employees: 292
Back to stocks